MEGAN GRANCHELLI: Open Payments
NPI 1962904607 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$205 in 10 payments from 9 companies in 2025. Trend: 2023 $317 · 2024 $662 · 2025 $205
Food & beverage: $205
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 2 | $34 |
| Insulet Corporation | 1 | $27 |
| Edwards Lifesciences Corporation | 1 | $27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| Exact Sciences Corporation | 1 | $22 |
| Novo Nordisk Inc | 1 | $20 |
| Amgen Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: TRELEGY ELLIPTA, Omnipod, XIFAXAN, The Cologuard Plus Collection Kit, Ozempic, EVENITY, MOUNJARO, CAMZYOS.
Industry payments across NY — which companies pay providers there.
